Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of 5-aminolevulinic acid in early Alzheimer's disease
jRCTs041180135Active, not recruiting
- Sponsor
- SBI Pharmaceuticals
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of 5-aminolevulinic acid in Alzheimer's disease (AD) (2 arms), sponsored by SBI Pharmaceuticals. Primary endpoints: Change in MMSE score from baseline to 52 weeks and Change in CDR score from baseline to 52 weeks. Started Jan 2017; status: active, not recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCTs041180135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180135.